drug licensing

Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring…

Licensing deals struck by Chinese biotech start-ups with overseas partners could potentially fetch billions in revenue if their drug candidates…